References for Myelomeningoceles in Children

  1. Dias MS, McLone DG: Myelomeningocele. in Albright AL, Pollack IF, Adelson PD (ed): Principles and practice of pediatric neurosurgery. New York: Thieme, 2008, pp338-366
  2. McClugage SG, Watanabe K, Shoja MM, et al. The history of the surgical repair of spina bifida. Childs Nerv Syst 28:1693-700, 2012
  3. Lorber J. Selective treatment of myelomeningocele: To treat or not to treat? Pediatrics 53:307-8, 1974
  4. Lorber J. Myelomeningocele; new approaches to its management. Nurs Times 70:272-3, 1974
  5. Lorber J. Results of treatment of myelomeningocele. An analysis of 524 unselected cases, with special reference to possible selection for treatment. Dev Med Child Neurol 13:279-303, 1971
  6. McLone DG. Treatment of myelomeningocele: arguments against selection. Clin Neurosurg 33:359-70, 1986
  7. McLone DG. Results of treatment of children born with a myelomeningocele. Clin Neurosurg 1983;30:407-12, 1983
  8. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 364:993-1004, 2011
  9. Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350:134-42. 2004
  10. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151:862-77, 2000
  11. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 262:2847-52, 1989
  12. O’Rahilly R, Muller F. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratology 65:162-70, 2002
  13. Khoury MJ, Beaty TH, Liang KY. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 127:674-83, 1988
  14. Melvin EC, George TM, Worley G, et al. Genetic studies in neural tube defects. NTD Collaborative Group. Pediatr Neurosurg 32:1-9, 2000
  15. George TM, Cummings TJ. The immunohistochemical profile of the myelomeningocele placode: is the placode normal? Pediatr Neurosurg 39:234-9, 2003
  16. Vujkovic M, Steegers EA, Looman CW, et al. The maternal Mediterranean dietary pattern is associated with a reduced risk of spina bifida in the offspring. BJOG 116:408-15, 2009
  17. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 33:145-58, 1999
  18. Corti G, Manzur T, Nagle C, et al. Etiopathology of Arnold-Chiari malformation: a fetal rat model of dysraphism. Fetal Diagn Ther 28:28-33, 2010
  19. Chatkupt S, Skurnick JH, Jaggi M, et al. Study of genetics, epidemiology, and vitamin usage in familial spina bifida in the United States in the 1990s. Neurology 44:65-70, 1994
  20. Copp AJ, Greene ND. Neural tube defects: prevention by folic acid and other vitamins. Indian J Pediatr 67:915-21, 2000
  21. Burger PC, Scheithauer BW, Vogel FS. Spine and epidural space, in Burger PC, Scheithauer BW, Vogel FS (eds): Surgical pathology of the nervous system and its coverings, ed 1. New York: Churchill Livingstone, 2002, pp 499-526
  22. Sakai Y. Neurulation in the mouse: manner and timing of neural tube closure. Anat Rec 223:194-203, 1989
  23. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci 93: 15227-32, 1996
  24. Jirtle RL, Sander M, Barrett JC. Genomic imprinting and environmental disease susceptibility. Environ Health Perspect 108:271-8, 2000
  25. Speer MC, Worley G, Mackey JF, et al. The thermolabile variant of methylenetetrahydrofolate reductase (MTHFR) is not a major risk factor for neural tube defect in American Caucasians. The NTD Collaborative Group. Neurogenetics 1:149-50, 1997
  26. Speer MC, Nye J, McLone D, et al. Possible interaction of genotypes at cystathionine beta-synthase and methylenetetrahydrofolate reductase (MTHFR) in neural tube defects. NTD Collaborative Group. Clin Genet 56:142-4, 1999
  27. Sadler TW, Merrill AH, Stevens VL, et al. Prevention of fumonisin B1-induced neural tube defects by folic acid. Teratology 66:169-76, 2002
  28. Gaskill SJ. Primary closure of open myelomeningocele. Neurosurg Focus 16 (2):E3, 2004.
  29. Pang D. Surgical complications of open spinal dysraphism. Neurosurg Clin N Am 6:243-57, 1995
  30. Teo C, Jones R. Management of hydrocephalus by endoscopic third ventriculostomy in patients with myelomeningocele. Pediatr Neurosurg 25:57-63, 1996
  31. Warf BC, Campbell JW. Combined endoscopic third ventriculostomy and choroid plexus cauterization as primary treatment of hydrocephalus for infants with myelomeningocele: long-term results of a prospective intent-to-treat study in 115 East African infants. J Neurosurg Pediatr 2(5):310-6, 2008
  32. Pollack IF, Kinnunen D, Albright AL. The effect of early craniocervical decompression on functional outcome in neonates and young infants with myelodysplasia and symptomatic Chiari II malformations: results from a prospective series. Neurosurgery 38:703-10; discussion 10, 1996
  33. McLone DG, Dias MS. Complications of myelomeningocele closure. Pediatr Neurosurg 17:267-73, 1991
  34. Iskandar BJ, Sansone JM, Medow J, et al. The use of quick-brain magnetic resonance imaging in the evaluation of shunt-treated hydrocephalus. J Neurosurg 2004;101:147-51, 2004
  35. Abrams P, Blaivas JG, Fowler CJ, et al. The role of neuromodulation in the management of urinary urge incontinence. BJU Int 91:355-9, 2003
  36. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003;62:28-37; discussion 40-2, 2003
  37. Pollack IF, Pang D, Albright AL, et al.Outcome following hindbrain decompression of symptomatic Chiari malformations in children previously treated with myelomeningocele closure and shunts. J Neurosurg. 1992 Dec;77(6):881-8.
  38. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-78, 2002
  39. Abrams P, Mattiasson A, Lose GR, et al. The role of desmopressin in the treatment of adult nocturia. BJU Int 90 Suppl 3:32-6, 2002
  40. Brinker MR, Rosenfeld SR, Feiwell E, et al. Myelomeningocele at the sacral level. Long-term outcomes in adults. J Bone Joint Surg Am 76:1293-300, 1994
  41. Swank M, Dias L. Myelomeningocele: a review of the orthopaedic aspects of 206 patients treated from birth with no selection criteria. Dev Med Child Neurol 34:1047-52, 1992
  42. Williams EN, Broughton NS, Menelaus MB. Age-related walking in children with spina bifida. Dev Med Child Neurol 1999; 41(7):446-9
  43. Bowman RM, McLone DG, Grant JA, et al. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg 34:114-20, 2001
  44. Hoppenfeld S. Congenital kyphosis in myelomeningocele. J Bone Joint Surg Br 49:276-80, 1967
  45. Main DM, Mennuti MT. Neural tube defects: issues in prenatal diagnosis and counselling. Obstet Gynecol 67:1-16, 1986
  46. Steinbok P, Irvine B, Cochrane DD, et al. Long-term outcome and complications of children born with meningomyelocele. Childs Nerv Syst 8:92-6, 1992
  47. Hall JG, Friedman JM, Kenna BA, et al. Clinical, genetic, and epidemiological factors in neural tube defects. Am J Hum Genet 43: 827-837, 1988
  48. Smith GK. The history of spina bifida, hydrocephalus, paraplegia, and incontinence. Pediatr Surg Int 2001;17:424-32.
  49. Pruitt LJ. Living with spina bifida: a historical perspective. Pediatrics 2012;130:181-3.
  50. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257-61.
  51. Zimmerman RD, Breckbill D, Dennis MW, et al. Cranial CT findings in patients with meningomyelocele. AJR Am J Roentgenol 1979;132:623-9.
  52. Talamonti G, D’Aliberti G, Collice M. Myelomeningocele: long-term neurosurgical treatment and follow-up in 202 patients. J Neurosurg 2007;107:368-86.
  53. Sarwark JF. Spina bifida. Pediatr Clin North Am 1996;43:1151-8.
  54. Rodriguez JI, Garcia M, Morales C, et al. Trisomy 13 syndrome and neural tube defects. Am J Med Genet 1990;36:513-6.
  55. Chemke J, Fishel E, Zalish M, et al. Multiple skeletal anomalies in the “13q-” syndrome. Eur J Pediatr 1978;128:27-31.
  56. Holmes LB, Driscoll SG, Atkins L. Etiologic heterogeneity of neural-tube defects. N Engl J Med 1976;294:365-9.
  57. Rabb CH, McComb JG, Raffel C, et al. Spinal arachnoid cysts in the pediatric age group: an association with neural tube defects. J Neurosurg 1992;77:369-72.
  58. Niggemann B, Buck D, Michael T, et al. Latex allergy in spina bifida: at the turning point? J Allergy Clin Immunol 2000;106:1201.
  59. Messing-Junger M, Rohrig A. Primary and secondary management of the Chiari II malformation in children with myelomeningocele. Childs Nerv Syst 2013;29:1553-62.
  60. Roach JW, Short BF, Saltzman HM. Adult consequences of spina bifida: a cohort study. Clin Orthop Relat Res 2011; 469(5):1246-52